

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
NOT FOR RELEASE, PUBLICATION AND DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.



GLOBAL HEALTH LIMITED

Our Company was incorporated as 'Global Health Private Limited' on August 13, 2004 at New Delhi, India as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation by the Registrar of Companies, Delhi and Haryana at Delhi ("RoC"). Our Company was then converted into a public limited company under the Companies Act, 2013, pursuant to a special resolution passed by our Shareholders at the EGM held on July 31, 2021 and consequently, the name of our Company was changed to 'Global Health Limited' and a fresh certificate of incorporation dated August 11, 2021 was issued by the RoC. For further details in relation to changes in the name and the registered office of our Company, see "History and Certain Corporate Matters" on page 257 of the Red Herring Prospectus dated October 22, 2022 filed with the RoC read together with the addendum to the Red Herring Prospectus dated October 27, 2022 ("RHP").

Registered Office: Medanta – Mediclinic, E-18, Defence Colony, New Delhi, Delhi 110 024, India; Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana 122 001, India;
Contact Person: Rahul Ranjan, Company Secretary and Compliance Officer; Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org; Corporate Identity Number: U85110DL2004PLC128319

OUR PROMOTER: DR. NARESH TREHAN

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF GLOBAL HEALTH LIMITED (OUR "COMPANY" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES BY OUR COMPANY AGGREGATING UP TO ₹5,000 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 50,761,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION (THE "OFFER FOR SALE") COMPRISING UP TO 50,661,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY ANANT INVESTMENTS (THE "INVESTOR SELLING SHAREHOLDER") AND UP TO 100,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY SUNIL SACHDEVA (JOINTLY HELD WITH SUMAN SACHDEVA) (THE "INDIVIDUAL SELLING SHAREHOLDERS", AND ALONG WITH INVESTOR SELLING SHAREHOLDER, THE "SELLING SHAREHOLDERS" AND SUCH EQUITY SHARES OFFERED BY THE SELLING SHAREHOLDERS, THE "OFFERED SHARES").THE OFFER SHALL CONSTITUTE [●]% OF THE FULLY DILUTED POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

QIB Portion: Not more than 50% of the Offer Non-Institutional Portion: Not less than 15% of the Offer
Retail Portion: Not less than 35% of the Offer
PRICE BAND: ₹ 319 TO ₹ 336 PER EQUITY SHARE OF FACE VALUE OF ₹ 2 EACH.
THE FLOOR PRICE IS 159.50 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 168 TIMES THE FACE VALUE OF THE EQUITY SHARES.
BIDS CAN BE MADE FOR A MINIMUM OF 44 EQUITY SHARES AND IN MULTIPLES OF 44 EQUITY SHARES THEREAFTER.

Risks to Investors

- Pursuant to the completion of the transfer of Equity Shares by Anant Investments (i.e., Investor Selling Shareholder) pursuant to the SPAs (defined below), please see below the weighted average price for all Equity Shares acquired in three years, 18 months and one year preceding the date of this Statutory Advertisement is set out below:

Period	Weighted average cost of acquisition# (in ₹)	Cap Price is 'X' times the Weighted Average Cost of Acquisition#	Range of acquisition price per equity share: Lowest Price – Highest Price** (in ₹)
Last three years	302.55**	1.11	115 - 336**
Last 18 months	302.55**	1.11	115 - 336**
Last one year	334.22**	1.01	329.10 - 336**

#Excludes details in relation to Equity Shares acquired by shareholders pursuant to exercise of employee stock options held by them under the ESOP Schemes of the Company.

***While determining the 'Highest Price' of acquisition and the weighted average cost of acquisition, we have not considered the following allotment: On December 18, 2013, 466,954 CCPS were allotted to Anant Investments (i.e., the Investor Selling Shareholder) for an aggregate consideration of ₹324,999,984 (i.e., ₹696 per CCPS). On January 4, 2022, the aforementioned 466,954 CCPS held by Anant Investments (i.e., the Investor Selling Shareholder) were converted into an aggregate of five Equity Shares in accordance with the terms of the 2013 SHA, read with the agreement dated January 4, 2022, among our Company, Anant Investments (i.e., Investor Selling Shareholder) and our Promoter. No additional consideration was paid at the time of such conversion.*

**On October 25, 2022, Anant Investments (i.e., Investor Selling Shareholder) has, pursuant to share purchase agreements each dated October 20, 2022 ("SPAs"), transferred an aggregate of 14,339,005 Equity Shares, representing 5.66% of the pre-Offer Equity Share capital of our Company (on a fully diluted basis)("Sale Shares"), comprising: (i) 4,779,669 Equity Shares to RJ Corp Limited, (ii) 1,045,552 Equity Shares to SBI Healthcare Opportunities Fund and 3,734,116 Equity Shares to SBI Small Cap Fund and (iii) 4,779,668 Equity Shares to Novo Holdings A/S, at a price of ₹ 336 per Equity Share.*

- Our subsidiaries, MHPL has incurred losses of ₹548.68 million and ₹121.23 million in Fiscal 2020 and Fiscal 2021 respectively and GHPL has incurred losses of ₹125.39 million, ₹163.54 million and ₹458.13 million in Fiscal 2020, Fiscal 2021 and Fiscal 2022 respectively.
- The total income contribution by our Company in Gurugram, Indore and Ranchi hospitals to consolidated total income in Fiscal 2022 was 81.60%. Any loss of business or disruption in the operations of these hospitals could have an adverse effect on the business and financial condition of our Company.
- We have five hospitals and six multi-speciality clinics in operation. Any loss of business or disruption in the operations of these hospitals and clinics could have an adverse effect on the business and financial condition of our Company.
- We have one under construction hospital which has faced delays in construction in past and we may experience further such delays.
- Our dependency on doctors, nurses and other healthcare professionals is significantly high. In case we are unable to attract/retain such professionals our business will be adversely impacted. In the past three fiscals and three months ended June 30, 2022, we have experienced attrition rates between 10.53% to 33.79% for doctors, 11.40% to 71.45% for nurses and 4.61% to 19.91% for other healthcare professionals.
- Average cost of acquisition of Equity Shares for Anant Investments (i.e, Investor Selling Shareholder) and Sunil Sachdeva (jointly with Suman Sachdeva) (i.e., Individual Selling Shareholders) is ₹145.60 and ₹2.02, respectively, and offer price at upper end of the price band is ₹336. Anant Investments has transferred an aggregate of 14,339,005 Equity Shares on October 25, 2022 for ₹336 per Equity Share.
- Certain financial ratios of the Company based on Fiscal 2022

Particulars	At floor price	At cap price
P/E Ratio	41.06	43.24
Market capitalization to revenue from operations (i.e. market value to turnover ratio)	3.73	3.93
Market capitalization to total income (i.e. market capitalization to earnings)	3.66	3.86
EV to EBITDA	17.16	18.04

- Weighted Average Return on Net Worth for Fiscals 2022, 2021 and 2020 is 7.21%.
- The four Book Running Lead Managers associated with the Offer have handled 53 public issues in the past three years out of which 13 issues closed below the issue price on listing date:

Name of the BRLMs	Total Issues	Issues closed below IPO Price on listing date
Kotak Mahindra Capital Company Limited*	14	4
Credit Suisse Securities (India) Private Limited*	2	2
Jefferies India Private Limited*	1	-
JM Financial Limited*	19	3
Common issues of above BRLMs	17	4
Total	53	13

**Issues handled where there were no common BRLMs.*

For further details and definitions please refer the RHP.

Indus Towers profit plunges 44% in Q2

Airtel Africa Q2 profit drops 18%

Accepts Voda Idea's proposal for softer payment terms

JATIN GROVER
New Delhi, October 27

INDUS TOWERS ON Thursday reported a weak financial performance for the September quarter which can be attributed to collection challenges faced by the company from its clients. In the September quarter, the company's consolidated net profit fell 44% year-on-year to ₹872 crore, whereas its revenue from operations rose 16% y-o-

y to ₹7,967 crore. Sequentially, the net profit rose 83%, whereas revenue rose 15.5%. On a y-o-y basis, the fall in net profit was due to provision of doubtful debts amounting to ₹1,771 crore made by the company during the quarter. While it did not name the company for which it has created the bad debt provision, it is likely for one of its key customers, Vodafone Idea, which owes it about ₹7,000 crore. In the preceding quarter too, the company made a one-time provision for doubtful debts worth ₹1,230 crore. Vodafone Idea has also asked Indus Towers for softer payment terms and proposed to

pay part of the amount to be billed till December 31, 2022, and 100% of the said amounts billed from January 2023. "Post discussions, the company has agreed to accept the part payment till December 2022," Indus Towers said in its earnings statement. The dues outstanding till December 2022 will be paid by Vodafone Idea between January and July 2023. Indus Towers had recently asked Vodafone Idea to either clear its dues or lose access to towers by November.

The company's Ebitda margins fell by 17.6 percentage points y-o-y to 35.3%. The margins expanded by 160 basis points sequentially, which can be attributed to increase in revenues. Owing to weak collections from the clients, operating cash flows fell 39% y-o-y to ₹1,277 crore. In its board meeting, the company also approved raising of up to ₹2,000 crore by way of issuance of non-convertible debentures in one or more tranches on private placement basis, it said.

The company's revenue from operations rose 16% year-on-year to ₹7,967 crore

"We have delivered a strong operational performance during the quarter, underpinned by good demand for products across our portfolio. Our financial performance continues to be impacted by the collection challenges we face from one of our customers," said N Kumar, chairman and independent director of the company. "The launch of 5G services by two major operators within three months of spectrum auction underlines the strong role of infrastructure players in providing 5G-ready sites at speed. At Indus Towers, we stay excited and prepared to capitalise on the 5G opportunity," Kumar added.

FE BUREAU
New Delhi, October 27

BHARTI AIRTEL-OWNED Airtel Africa's net profit attributable to owners fell 18.4% quarter-on-quarter to \$133 million in the September quarter owing to an increase in finance costs driven by higher foreign exchange and derivative losses. Since the company operates in 14 countries within Africa, the depreciation of currencies against the dollar has a negative impact on its operations. While the net profit fell, revenue from operations rose 4% q-o-q to \$1.31 billion, largely due to an increase in consumer base. On a year-on-year basis, the company's net profit fell 17%,

while revenues rose nearly 13%. The company added 3.1 million subscribers, taking its total base to 134.7 million, higher than 131.6 million in the preceding quarter. Further, owing to increased usage across voice, data and mobile money, Airtel Africa's average revenue per user (Arpu) rose 3% sequentially to \$3.3. "While we are not immune to the current macroeconomic challenges and currency devaluation risks, I am pleased to report double-digit reported revenue growth in the period largely driven by customer growth of 9.7% and Arpu growth of 7.2% (for the half year ended September), as we increased penetration and

usage through our affordable service offerings," CEO Segun Ogunsanya said. Revenue from the voice business rose nearly 1% q-o-q to \$616 million, whereas its data revenue rose 6.7% to \$446 million. The mobile money business rose 8.8% to \$173 million. "Following the receipt of the Payment Service Bank and Super-Agent licence in Nigeria during the period, we have launched our mobile money operations. We are excited about the opportunity," Ogunsanya said. Apart from a decent topline growth, a major reason for the fall in net profit was higher finance cost for the company, which rose 36% q-o-q and 190% y-o-y to \$206 million.

BID/OFFER PROGRAMME

ANCHOR INVESTORS BIDDING DATE: WEDNESDAY, NOVEMBER 02, 2022⁽¹⁾

BID/OFFER OPENS ON: THURSDAY, NOVEMBER 03, 2022

BID/OFFER CLOSES ON: MONDAY, NOVEMBER 07, 2022⁽²⁾

⁽¹⁾ Our Company and the Investor Selling Shareholder, in consultation with the BRLMs, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period will be one Working Day prior to the Bid/Offer Opening Date i.e., Wednesday, November 02, 2022.
⁽²⁾ The UPI Mandate end time and date shall be 5:00 p.m. on Monday, November 07, 2022

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Investor Selling Shareholder may, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the other Designated Intermediaries and the Sponsor Banks, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs"), and such portion, the "QIB Portion", provided that our Company and the Investor Selling Shareholder may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, in accordance with the SEBI ICDR Regulations (the "Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allotment in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from the Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders ("Non-Institutional Portion") of which (a) one-third shall be available for allocation to Bidders with an application size of more than ₹200,000 and up to ₹1,000,000 and (b) two-thirds shall be available for allocation to Bidders with an application size of more than ₹1,000,000 provided that under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price, and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders ("Retail Portion") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All potential Bidders, other than Anchor Investors, are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (in case of UPI Bidders using UPI Mechanism), if applicable, in which the corresponding Bid Amounts will be blocked by the self-certified syndicate banks ("SCSBs") or the Sponsor Banks under the UPI Mechanism, as applicable, to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. See "Offer Procedure", on page 463 of the RHP.

Bidders/ Applicants should ensure that DP ID, PAN, Client ID and UPI ID (for RIBs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/ Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/ Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for RIBs bidding through the UPI mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/ Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic

Details would be at the Bidders'/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects of the Company, please see the section "History and Certain Corporate Matters" on page 257 of the RHP. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section titled "Material Contracts and Documents for Inspection" on page 497 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and Capital structure: As on the date of the RHP, the authorised share capital of the Company is ₹ 1,335,249,984 divided into 667,624,992 Equity Shares of face value of ₹2 each. The issued, subscribed and paid-up share capital of the Company is ₹ 506,607,860 divided into 253,303,930 Equity Shares of face value of ₹ 2 each. For details, please see the section titled "Capital Structure" beginning on page 125 of the RHP.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: The names of the signatories of the Memorandum of Association of our Company are Dr. Narsh Trehan and Sunil Sachdeva. For details of the share capital history and capital structure of our Company, please see the section titled "Capital Structure" beginning on page 125 of the RHP.

Listing: The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges being the BSE and the NSE. Our Company has received an 'in-principle' approval from each of the BSE and the NSE for the listing of the Equity Shares pursuant to their letters dated October 21, 2021 and October 22, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red Herring Prospectus and the Prospectus shall be delivered to the RoC in accordance with Sections 26(4) and 32 of the Companies Act. For details of the material contracts and documents that will be available for inspection from the date of the RHP up to the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 497 of the RHP.

Disclaimer Clause of the Securities and Exchange Board of India ("SEBI"): SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 437 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of NSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 443 of the RHP for the full text of the disclaimer clause of NSE.

Disclaimer Clause of BSE: It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 443 of the RHP for the full text of the disclaimer clause of BSE.

General Risk: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (the "SEBI"), nor does the SEBI guarantee the accuracy or adequacy of the contents of this RHP. Specific attention of the investors is invited to "Risk Factors" on page 41 of the RHP.

ASBA[#]

Simple, Safe, Smart way of Application!!!

Mandatory in public issues. No cheque will be accepted.

[#]Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA below.

UPI

UNIFIED PAYMENTS INTERFACE

UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to ₹ 500,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. Retail Individual Bidders and Non-Institutional Bidders also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by Retail Individual Bidders in the Retail Portion and Non-Institutional Bidders with an application size of up to ₹ 500,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Offer Procedure" on page 463 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges" and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=35 and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. RIBs Bidding using the UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. HDFC Bank Limited and Kotak Mahindra Bank Limited have been appointed as Sponsor Banks for the Offer, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For offer related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail id: ipo.upi@npci.org.in.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
					<div>Rahul Ranjan Company Secretary and Compliance Officer Tel: +91 124 483 4060 E-mail: compliance@medanta.org Website: https://www.medanta.org</div> <div>Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-credit of funds by electronic mode, etc. For All Offer related queries and for redressal of complaints, Investors may also write to the BRLMs.</div>
<div>Kotak Mahindra Capital Company Limited 1st Floor, 27BKC, Plot No. C - 27 G Block, Bandra Kurla Complex, Bandra (East) Mumbai 400 051, Maharashtra, India Tel: +91 22 4336 0000 E-mail: globalhealth ipo@kotak.com Investor grievance e-mail: kmccredressa@kotak.com Website: www.investmentbank.kotak.com Contact Person: Ganesh Rane SEBI Registration No: INM000008704</div>	<div>Credit Suisse Securities (India) Private Limited 9th Floor, Ceejay House, Plot F, Shivsagar Estate Dr. Annie Besant Road, Worli, Mumbai 400 018 Maharashtra, India Tel: +91 22 6777 3885 E-mail: list.medantaipo2021@credit-suisse.com Investor grievance e-mail: list.icellmer-bnkg@credit-suisse.com Website: https://www.credit-suisse.com/in/en/investment-banking-apac/investment-banking-in-india/ipo.html Contact Person: Abhishek Joshi SEBI Registration No.: INM000011161</div>	<div>Jefferies India Private Limited 42/43, 2 North Avenue Maker Maxity Bandra-Kurla Complex, Bandra (East) Mumbai 400 051, Maharashtra, India Tel: +91 22 4356 6000 E-mail: medanta.ipo@jefferies.com Investor grievance e-mail: jipl.grievance@jefferies.com Website: www.jefferies.com Contact Person: Ashutosh Prajapati SEBI Registration No.: INM000011443</div>	<div>JM Financial Limited 7th Floor, Chergy, Appasaheb Marathe Marg Prabhadevi, Mumbai 400 025 Maharashtra, India Tel: +91 22 6630 3030 E-mail: ghl.ipo@jmfml.com Investor grievance e-mail: grievance.ibl@jmfml.com Website: www.jmfml.com Contact Person: Prachee Dhuri SEBI Registration Number: INM000010361</div>	<div>KFin Technologies Limited (formerly known as KFin Technologies Private Limited) Selenium, Tower-B, Plot 31 and 32, Financial District Nanakramguda, Serilingampally Hyderabad, Rangareddi 500 032, Telangana, India Tel: +91 40 6716 2222 E-mail: globalhealth.ipo@kfintech.com Investor grievance e-mail: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: Murali Krishna SEBI Registration No.: INR000000221</div>	

Availability of the RHP: Investors are advised to refer to the RHP and the "Risk Factors" beginning on page 41 of the RHP, before applying in the Offer. A copy of the RHP shall be available on website of SEBI at www.sebi.gov.in and is available on the websites of the BRLMs, i.e. Kotak Mahindra Capital Company Limited at www.investment-bank.kotak.com, Credit Suisse Securities (India) Private Limited at <https://www.credit-suisse.com/in/en/investment-banking-apac/investment-banking-in-india/ipo.html>, Jefferies India Private Limited at www.jefferies.com and JM Financial Limited at www.jmfml.com respectively and on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

Availability of Bid-cum-Application Forms: Bid-cum-Application Forms can be obtained from the Registered Office of the Company Global Health Limited, Tel: +91 124 483 4060; the BRLMs: Kotak Mahindra Capital Company Limited, Tel: +91 22 4336 0000, Credit Suisse Securities (India) Private Limited, Tel: +91 22 6777 3885, Jefferies India Private Limited, Tel: +91 22 4356 6000 and JM Financial Limited, Tel: +91 22 6630 3030 and at the select locations of the Sub-syndicate Members. (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

Sub-syndicate member: Almondz Global Securities Limited, Amrapali Capital & Finance Services Limited, Anand Rathi Share & Stock Brokers Limited, Axis Capital Limited, Centrum Broking Limited, Dalal & Broacha Stock Broking Private Limited, Edelweiss Broking Limited, Eurekha Stock & Share Brokers Limited, Finwizard Technology Pvt Limited, Globe Capital Markets Limited, HDFC Securities Limited, ICICI Securities Limited, IDBI Capital Markets and Securities Limited, IIFL Securities Limited, JM Financial Services Limited, Jobanputra Fiscal Services Private Limited, KJMC Capital Markets Limited, LKP Securities Limited, Motilal Oswal Securities Limited, Nirmal Bang Securities Pvt. Limited, Prabhudas Lilladher Pvt Limited, Pravin Ratilal Share & Stock Brokers Limited, Religare Broking Limited, RR Equity Brokers Private Limited, SBICAP Securities Limited, Sharekhan Limited, SMC Global Securities Limited, Systematix Shares and Stock Brokers Limited, Tradebulls Securities Limited and YES Securities (India) Limited.

Escrow Collection Bank, Refund Bank, and Public Offer Bank: HDFC Bank Limited

Sponsor Banks: HDFC Bank Limited and Kotak Mahindra Bank Limited

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: New Delhi
Date: October 27, 2022

Global Health Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its equity shares ("Offer") and has filed a Red Herring Prospectus ("RHP") with the Registrar of Companies, Delhi & Haryana at Delhi ("RoC"). The RHP is available on the website of the SEBI at www.sebi.gov.in, the website of the National Stock Exchange of India Limited at www.nseindia.com and the website of the BSE Limited at www.bseindia.com and the respective websites of the book running lead managers to the Offer, Kotak Mahindra Capital Company Limited at www.investmentbank.kotak.com, Credit Suisse Securities (India) Private Limited at <https://www.credit-suisse.com/in/en/investment-banking-apac/investment-banking-in-india/ipo.html>, Jefferies India Private Limited at www.jefferies.com and JM Financial Limited at www.jmfml.com. Investors should note that investment in equity shares involves a high degree of risk. For details, potential investors should refer to the RHP filed with the RoC, including the section titled "Risk Factors" on page 41 of the RHP.

Potential investors should not rely on the DRHP filed with the SEBI in making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to "qualified institutional buyers" (as defined in Rule 144A and referred to in the Red Herring Prospectus as "U.S. QIBs") in private transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering in the United States.

CRISIL Disclaimer: CRISIL Research, a division of CRISIL Limited (CRISIL) has taken due care and caution in preparing this report (Report) based on the information obtained by CRISIL from sources which it considers reliable (Data). CRISIL does not guarantee the accuracy, adequacy or completeness of any material contained in or referred to in Report. This Report is not a recommendation to invest / disinvest in any entity covered in the Report and no part of this Report should be construed as an expert advice or investment banking within the meaning of any law or regulation. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary permission and/or registration to carry out its business activities in this regard. Global Health Limited will be responsible for ensuring compliances and consequences of non-compliances for use of the Report or part thereof outside India. CRISIL Research operates independently of, and does not have access to information obtained by CRISIL Ratings Limited / CRISIL Risk and Infrastructure Solutions Ltd (CRIS), which may, in their regular operations, obtain information of a confidential nature. The views expressed in this Report are that of CRISIL Research and not of CRISIL Ratings Limited / CRIS. No part of this Report may be published/reproduced in any form without CRISIL's prior written approval.

Adfactors